RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient
04. Januar 2024 08:45 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...